EA201391334A1 - Ингибиторы hsp90 - Google Patents

Ингибиторы hsp90

Info

Publication number
EA201391334A1
EA201391334A1 EA201391334A EA201391334A EA201391334A1 EA 201391334 A1 EA201391334 A1 EA 201391334A1 EA 201391334 A EA201391334 A EA 201391334A EA 201391334 A EA201391334 A EA 201391334A EA 201391334 A1 EA201391334 A1 EA 201391334A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
formulas
methods
hsp90 inhibitors
amount
Prior art date
Application number
EA201391334A
Other languages
English (en)
Inventor
Вейлин Сан
Тони Толдоун
Паллав Пател
Габриэла Чиозис
Original Assignee
Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч filed Critical Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч
Publication of EA201391334A1 publication Critical patent/EA201391334A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Abstract

Настоящее изобретение относится к соединениям формул (IA) и (IB):и фрамацевтически приемлемым солям таких соединений, где Z, Z, Z, Ха, Xb, Xc, Xd, Y, Хи Химеют значения, определенные в описании, композициям, содержащим эффективное количество соединения формулы (IA) и/или (IB), и способам предотвращения заболевания, такого как рак с повышенной экспрессией Her-киназ, включающим введение нуждающемуся в этом пациенту эффективного количества соединений формул (IA) и (IB), в которых Хпредставляет собой уходящую группу для введения радиомеченного атома, такого какI илиI, и к способам применения таких соединений в изготовлении радиомеченных соединений, в частности, для применения в визуализации.
EA201391334A 2011-04-05 2012-04-05 Ингибиторы hsp90 EA201391334A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472061P 2011-04-05 2011-04-05
PCT/US2012/032371 WO2012138894A1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Publications (1)

Publication Number Publication Date
EA201391334A1 true EA201391334A1 (ru) 2014-06-30

Family

ID=48166734

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391334A EA201391334A1 (ru) 2011-04-05 2012-04-05 Ингибиторы hsp90

Country Status (11)

Country Link
US (2) US9346808B2 (ru)
EP (1) EP2694505B1 (ru)
JP (1) JP6266506B2 (ru)
KR (1) KR102010222B1 (ru)
CN (1) CN103582642B (ru)
AU (1) AU2012240077C1 (ru)
BR (1) BR112013025634A2 (ru)
CA (1) CA2832530C (ru)
EA (1) EA201391334A1 (ru)
MX (1) MX360390B (ru)
WO (1) WO2012138894A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP3305297A1 (en) 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
CN105924443A (zh) 2009-10-07 2016-09-07 斯隆-凯特林癌症研究院 用作Hsp90抑制剂的嘌呤衍生物
BR112013025761A2 (pt) 2011-04-05 2018-05-29 Sloan Kettering Inst Cancer Res inibidores de hsp90
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
ES2624982T3 (es) * 2011-07-08 2017-07-18 Sloan-Kettering Institute For Cancer Research Usos de inhibidores etiquetados HSP90
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
CA2934850C (en) * 2013-12-23 2022-12-06 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CN113521314A (zh) 2014-09-17 2021-10-22 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EP3359196B1 (en) 2015-10-05 2022-03-16 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
AU2018290288A1 (en) * 2017-06-23 2020-01-16 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
EP1169319A4 (en) 1999-04-09 2005-02-09 Sloan Kettering Institutefor C METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY
KR100850727B1 (ko) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
JP2005505506A (ja) 2001-06-12 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な大環状分子
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
IL163688A0 (en) 2002-02-28 2005-12-18 Astrazeneca Ab 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and theiruse as antibacterial agents
WO2004094647A2 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
WO2005028434A2 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2634723A1 (en) 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
NZ572600A (en) * 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
EP3305297A1 (en) 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
FR2906824B1 (fr) 2006-10-09 2008-12-26 Roger Mondelin Sas Soc Par Act Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
EA019103B1 (ru) 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
US20100240656A1 (en) 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
WO2009065035A1 (en) 2007-11-14 2009-05-22 Myriad Genetics, Inc. Therapeutic compounds and their use in treating diseases and disorders
US8722703B2 (en) 2009-01-16 2014-05-13 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
CN105924443A (zh) 2009-10-07 2016-09-07 斯隆-凯特林癌症研究院 用作Hsp90抑制剂的嘌呤衍生物
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
BR112013025761A2 (pt) 2011-04-05 2018-05-29 Sloan Kettering Inst Cancer Res inibidores de hsp90
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도

Also Published As

Publication number Publication date
AU2012240077B2 (en) 2017-04-20
JP6266506B2 (ja) 2018-01-24
MX360390B (es) 2018-10-31
US20160264577A1 (en) 2016-09-15
CA2832530A1 (en) 2012-10-11
KR102010222B1 (ko) 2019-08-13
AU2012240077C1 (en) 2017-08-10
US9346808B2 (en) 2016-05-24
BR112013025634A2 (pt) 2016-07-19
CA2832530C (en) 2021-02-16
AU2012240077A1 (en) 2013-10-31
CN103582642B (zh) 2021-05-11
EP2694505B1 (en) 2022-04-27
MX2013011532A (es) 2014-08-22
KR20140062429A (ko) 2014-05-23
US9926321B2 (en) 2018-03-27
WO2012138894A1 (en) 2012-10-11
JP2014510148A (ja) 2014-04-24
CN103582642A (zh) 2014-02-12
NZ616758A (en) 2016-01-29
US20140088121A1 (en) 2014-03-27
WO2012138894A4 (en) 2012-12-06
EP2694505A1 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
EA201391334A1 (ru) Ингибиторы hsp90
EA201391337A1 (ru) Ингибиторы hsp90
PH12016501204A1 (en) Syk inhibitors
GEP201706699B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
NZ715747A (en) Syk inhibitors
NZ603155A (en) Phospholipid drug analogs
MD20130095A2 (ru) Конденсированные соединения бензоксазепинонов в качестве модуляторов ионных каналов
NZ611866A (en) Spiro-oxindole mdm2 antagonists
MX349159B (es) Derivados deuterados de ivacaftor.
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
MX2013014843A (es) Oxazepinas como moduladores del canal de iones.
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
PE20140604A1 (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
MX2015008187A (es) Inhibidores de alk deuterados.
EA201490573A1 (ru) Соединение бензотиазолона
EA201100502A1 (ru) Гликозидные производные и их применения